Literature DB >> 14624148

Bone density improves with disease remission in patients with inflammatory bowel disease.

David M Reffitt1, John Meenan, Jeremy D Sanderson, Ravin Jugdaohsingh, Jonathan J Powell, Richard P Thompson.   

Abstract

BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) are at risk of low bone mineral density (BMD). The aim of this cross-sectional study was to investigate (i) whether patients with IBD in long-term remission have greater bone density relative to patients with active disease, (ii) the effect of remission on BMD in ulcerative colitis and Crohn's disease, and (iii) the effect of azathioprine treatment, used to induce remission, on BMD. PATIENTS AND METHODS: BMD relative to the age-standardised mean (Z-score) was measured by dual-energy X-ray absorptiometry at the left femoral neck and lumbar spine in consecutive patients with IBD. Patients were divided into the following groups: (i) active disease, (ii) remission of less than one year, (iii) remission of one to three years, and (iv) remission of more than three years. Active disease was defined as three or more bowel motions per day, treatment with oral or rectal corticosteroids, and/or presence of a fistula. The subgroups with ulcerative colitis and Crohn's disease and the effect of taking azathioprine were compared. All results were controlled for confounding variables. RESULTS A total of 137 (64 ulcerative colitis, 73 Crohn's disease) patients were evaluated. Patients in remission for more than three years had a normal mean Z-score that was significantly higher than those with active disease at both the femoral neck and the lumbar spine for both ulcerative colitis and Crohn's disease. Patients taking azathioprine and in remission had significantly higher mean Z-scores at the lumbar spine than patients with active disease and who were not taking azathioprine.
CONCLUSION: In patients with ulcerative colitis and Crohn's disease, age-matched BMD is higher with increasing duration of disease remission and induction of remission by azathioprine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624148     DOI: 10.1097/00042737-200312000-00003

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  13 in total

1.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

Review 2.  Drug therapy for ulcerative colitis.

Authors:  Chang-Tai Xu; Shu-Yong Meng; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

3.  Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease.

Authors:  Jason Soo; Bushra A Malik; Justine M Turner; Rabin Persad; Eytan Wine; Kerry Siminoski; Hien Q Huynh
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

Review 4.  Extraintestinal manifestations in inflammatory bowel disease.

Authors:  Silvio Danese; Stefano Semeraro; Alfredo Papa; Italia Roberto; Franco Scaldaferri; Giuseppe Fedeli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 5.  Inflammatory bowel diseases as secondary causes of osteoporosis.

Authors:  Charles N Bernstein
Journal:  Curr Osteoporos Rep       Date:  2006-09       Impact factor: 5.096

Review 6.  Review article: vitamin D and inflammatory bowel diseases.

Authors:  V P Mouli; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2013-11-17       Impact factor: 8.171

7.  Colitis-induced bone loss is gender dependent and associated with increased inflammation.

Authors:  Regina Irwin; Taehyung Lee; Vincent B Young; Narayanan Parameswaran; Laura R McCabe
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

Review 8.  Risk factors for osteoporosis in inflammatory bowel disease patients.

Authors:  Carla Andrade Lima; Andre Castro Lyra; Raquel Rocha; Genoile Oliveira Santana
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 9.  Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Authors:  Guru Trikudanathan; Preethi G K Venkatesh; Udayakumar Navaneethan
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 10.  Osteoporosis in inflammatory bowel disease.

Authors:  Tauseef Ali; David Lam; Michael S Bronze; Mary Beth Humphrey
Journal:  Am J Med       Date:  2009-07       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.